1651 – 1660 of 2179
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2006
-
Mark
Pharmacoeconomics of factor dosing in the haemophilia population.
(
- Contribution to journal › Article
-
Mark
Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival.
(
- Contribution to journal › Article
-
Mark
Deregulation of cyclin D2 by juxtaposition with T-cell receptor alpha/delta locus in t(12;14)(p13;q11)-positive childhood T-cell acute lymphoblastic leukemia.
(
- Contribution to journal › Article
-
Mark
Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
(
- Contribution to journal › Article
-
Mark
Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation
(
- Contribution to journal › Article
-
Mark
Von Willebrand's disease: clinical management
(
- Contribution to journal › Article
-
Mark
Polymorphisms in the IL-10 but not in the IL-1{beta} and IL-4 genes are associated with inhibitor development in patients with hemophilia A.
(
- Contribution to journal › Article
-
Mark
Smad5 is dispensable for adult murine hematopoiesis.
(
- Contribution to journal › Article
-
Mark
Direct action on the molecule is one of several mechanisms by which ultrasound enhances the fibrinolytic effects of reteplase.
(
- Contribution to journal › Article
-
Mark
Practice patterns in haemophilia A therapy - global progress towards optimal care
(
- Contribution to journal › Article